India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...

-AFP Bayer AG said, on Tuesday, it was mulling ways to challenge a ground-breaking Indian ruling allowing a local firm to produce a vastly cheaper copy of a cancer drug made by the German pharmaceutical giant. The ruling on Monday by India's Controller-General of Patents marked the first time a so-called ‘compulsory licence' for production of a patented drug has been granted in India, known as a global generics drug powerhouse. Evaluating options “We...

In a landmark decision, India’s intellectual property office on Monday allowed Hyderabad-based Natco Pharma Ltd to make and sell a copycat version of German drug maker Bayer AG’s patented cancer treatment Nexavar. It’s the first time that an Indian company has been granted the so-called compulsory licence to market a generic version of a patented drug. The drug, patented by Bayer in India in 2008, is used in the treatment of...

In a landmark decision that could set a precedent on how life-saving drugs under patents can be made affordable, the government has allowed a domestic company, Natco Pharma, to manufacture a copycat version of Bayer's patented anti-cancer drug, Nexavar, bringing down its price by 97%. In the first-ever case of compulsory licencing approval, the Indian Patent Office on Monday cleared the application of Hyderabad's Natco Pharma to sell generic drug Nexavar,...

The apex decision-making body of the communications ministry has cleared the proposal to grant more powers to the Telecom Regulatory Authority of India (TRAI) and enable the watchdog to act like a civil court.  This puts TRAI on par with the Securities and Exchange Board of India and the Competition Commission of India and permits the telecom regulator to 'summon persons, examine them on oath, demand documents and evidence on affidavits...